European Archives - Page 319 of 1354 - European Medical Journal

Handshake on a green background

AstraZeneca pays $160m for FibroGen's China subsidary

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.

Tirzepatide Lowers Left Ventricular Mass and Fat in Obesity-Related HFpEF

Tirzepatide reduces LV mass and paracardiac fat in obesity-related HFpEF, offering structural heart benefits beyond weight loss.

How HCPs consumed medical content in 2024

This infographic explores how healthcare professionals engaged with medical content in 2024, highlighting their HCP content preferences and more.

Wearable Device Reduces Fatigue and Raynaud Symptoms in Systemic Sclerosis

A wearable device reduced fatigue and Raynaud symptoms in systemic sclerosis, improving quality of life without adverse effects.

Predicting Methotrexate Failure in Ectopic Pregnancy

A new retrospective study has identified key risk factors for methotrexate (MTX) treatment failure in tubal ectopic pregnancy (TEP). The findings suggest that higher gravidity and elevated β-hCG levels increase the likelihood of treatment failure, while additional MTX doses improve success rates.

Scientists Identify Genetic Variants That Drive Cancer Risk and Growth

Researchers uncover genetic variants that drive cancer risk, revealing new therapeutic targets and refining genetic screening strategies.

The Second Brain: Transforming Gut Healing: Part 2

In this second part of the podcast, Jonathan welcomes back Douglas Drossman, pioneer in disorders of gut-brain interaction.

STI Surge in Europe Sparks Public Health Concern

The ECDC’s Annual Epidemiological Reports analysed surveillance data from 29 EU/EEA countries, tracking trends in gonorrhoea, syphilis, and chlamydia.

Coeliac Disease Risk Drops with High-Fibre Diet in Infants

A new study suggests that infants who consume a high-fibre diet before their first birthday may have a significantly lower risk of developing celiac disease.

Which Treatment for Basal Cell Carcinoma is More Effective?

After five years, the probability of remaining free from treatment failure was 77.8% for patients who underwent superficial curettage.